![logo](/logos/TARS.webp)
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
30.59 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Tarsus Pharmaceuticals, Inc. |
Symbool | TARS |
Munteenheid | USD |
Prijs | 30.59 |
Beurswaarde | 1,163,695,603 |
Dividendpercentage | 0% |
52-weken bereik | 12.57 - 42.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bobak R. Azamian M.D. |
Website | https://www.tarsusrx.com |
An error occurred while fetching data.
Over Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)